News

Thornton & Ross News

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield, October 9, 2019 – Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

The technologically advanced 600 sqm bottling and filling line will be incorporated within the existing Thornton & Ross warehouse, in order to preserve the highest standards of hygiene.

The move is part of ambitious growth plans by Thornton & Ross – Huddersfield’s largest employer – and represents the most significant investments Thornton & Ross parent company, STADA, has made in the UK. Forty permanent jobs will be created at the site.

The process design and engineering work will be implemented by Haden Freeman, a process engineering consultancy headquartered in Denton.

Following a recommendation, Haden Freeman conducted an initial site visit and carried out checks for potential hazards before drawing up a detailed strategy for the new facility. A project manager was appointed along with site and office teams to ensure all work complied with Haden Freeman’s ISO:9001 2015 certified quality standards.

The building and civil engineering works will be completed by Hawkins Construction (Northern) Ltd, which is a well-established construction company specialising in this type of installation within a hygienic environment.

Hawkins Construction (Northern) Limited aims to deliver the new facility with minimal impact and without significant downtime on existing filling lines. Hawkins Construction and Haden Freeman already have an excellent working relationship, having recently worked together on number of challenging but successful projects within the manufacturing sector.

The scheme is expected to take 22 weeks to complete, with a completion date of January 1st 2020. Work will involve demolition and alterations to structures around existing production lines, structural steelwork and gantries, internal hygiene standard fire walls, walk on ceiling, Electrical & Mechanical design and installation, hygiene doors, stainless steel kerbs and specialist anti-dissipative hygienic flooring.

Mark Kirkup, Thornton & Ross Vice-President of UK Operations, said the new facility was essential in enabling the company to expand: “This facility represents the largest single investment that our parent company, the STADA Group, has made at our UK site and underlines the success of Thornton & Ross as a company.

“It will form an integral part of our plans to expand, which include the creation of 40 new permanent positions across the company.

“We selected our partners on this project for their technical capabilities and experience of working in similar environments. Despite the short timeframe for completion, we are extremely pleased with how the project is progressing and look forward to seeing the new bottling line in action.”

Shaun Sykes, Managing Director at Hawkins Construction, added: “Hawkins Construction are extremely proud to be involved with this project and look forward to working closely with Thornton & Ross and building our relationship with the project team involved. Our teams will ensure all work complies with our ISO:9001 2015 certified quality standards.”

Thornton & Ross develops, manufactures and supplies a wide range of branded over-the-counter medicines, dermatological solutions and other healthcare and hygiene products including Zoflora®, Hedrin® and Setlers®. It is part of the German-based STADA Group.

New Facilities Team 2019 New Facilities Team 2019
At the site of the new bottling facility are, from left: Paul Ward, project manager, Thornton & Ross; Roger Scarlett-Smith, Vice-President of UK Operations, Thornton & Ross; Shaun Sykes, Managing Director, Hawkins Construction; and Robert Warlow, Project Manager, Haden Freeman.
Thornton & Ross triumphant in industry awards

Huddersfield, October 4, 2019 – Huddersfield-based pharmaceutical company Thornton & Ross has received national recognition for six of its products at the national 2019 ‘Most Valuable Product’ (MVP) Awards in pharmacy.

The firm’s Nizoral® Anti-Dandruff Shampoo was voted winner in the Hair and Scalp Care category, while five other products were highly commended in their categories:

Child Health Care® Virasoothe
Cold & Cough Covonia® Chesty Cough Mixture
Cold & Cough Covonia Dry & Tickly Cough
Infant Gastrointestinal Care Co Lactase Drops
Sexual Health KY Jelly®

The awards are split into 28 categories covering a range of common conditions and health-related issues that consumers rely on pharmacy help and advice with.

The shortlist was chosen by an 18-strong expert panel including retail buyers and community pharmacists from across the UK from pharmacy brands including Boots, Tesco and Lloyds Pharmacy. Voting on all shortlisted products was opened out to all pharmacy staff in the UK, with thousands casting their votes.

Thornton & Ross now has the chance to secure the Overall MVP Award, which will be chosen by industry professionals attending The Pharmacy Show in October.

The overall winner will be revealed at The MVP 2019 Celebratory Lunch on 1 November in London. A cross functional team of 10 will be attending from Thornton & Ross.

Speaking about the awards success, head and executive vice-president of Thornton & Ross Roger Scarlett-Smith said: “We are thrilled with Thornton & Ross’s success at the MVP awards, particularly as this is the first year that we have submitted entries. To be recognized across six different categories, with a clear win for Nizoral, is a fantastic achievement and underlines our commitment to delivering the best quality products to our customers.”

Thornton & Ross develops, manufactures and supplies a wide range of branded over-the-counter medicines, dermatological solutions and other healthcare and hygiene products including Zoflora®, Hedrin® and Setlers®. It is part of the German-based STADA Group.

The business recently announced a recruitment drive to fill 40 positions it has created at its Linthwaite production site as it continues to expand.

Scarlett-Smith adds: “We have ambitious plans to strengthen our foothold across the UK pharmaceutical industry and in the first half of this year, we gained broad based growth across the range, from our Natures Aid® natural supplements, to Zoflora® in home hygiene, and to our prescription therapies for dermatology and myeloma. We recently closed our deal with GSK to acquire some well-known brands including Oilatum® and Savlon® skin care brands. These sales will add to growth in the second half of 2019.”

MVP Team 2019 Clockwise From bottom-left: Kelly Auty (Covonia), Anna Flowers (sales), Hannah Rice (sales), Jack Dearden (Care), Phoebe Buckley (KY Jelly and Nizoral), Amy Barker (Metanium and Tixylix)

Thornton & Ross launches alternative, cost-effective treatment for osteoporosis in UK

Huddersfield, September 10, 2019 – West Yorkshire-based pharmaceutical company Thornton & Ross (T&R) is launching an alternative, cost-effective treatment for osteoporosis.

Movymia® teriparatide was launched at the end of August, when the patent for Forsteo® teriparatide – the only approved osteoanabolic therapy for osteoporosis in the UK – expired.

Movymia® will offer the NHS a teriparatide which has been evaluated by the European Medicines Agency and deemed to be similar to Forsteo® teriparatide but at a more a cost-effective list price .

The product is injected using a refillable, multi-dose injection device called a Movymia® Pen, which is used for the entire treatment period – allowing the NHS to remain environmentally friendly.

Movymia® is the first of a significant pipeline of biosimilar products due to be launched by T&R and underlines the company’s commitment to providing the NHS with cost-effective treatment options. It complements T&R’s extensive bone health portfolio, which includes Fultium® D3, Accrete® D3 and Binosto®.

Roger Scarlett-Smith, T&R’s Executive Vice President UK, said: “The launch of Movymia® is an important expansion of the STADA group’s biosimilar portfolio in the UK, and is a sign of our ongoing commitment to improving treatment options for people living with osteoporosis.”

Alison Doyle, Head of Clinical and Operations at the Royal Osteoporosis Society, added: “We are delighted that teriparatide – an effective anabolic treatment for osteoporosis – is now available as a biosimilar following the expiration of the Forsteo® patent.

“This once expensive medication was rationed by NICE guidance until last year, when NHS England announced the treatment would be available to men as well as women. While we are aware that some men still struggle to get access to Teriparatide, the availability of biosimilars should drive down the cost of treatment and make it available to more people with osteoporosis.

“Improved choice in the current offering of clinically effective treatments for osteoporosis is welcome news for healthcare professionals and people with osteoporosis alike.

A biosimilar is a pharmaceutical product manufactured by using biotechnology with a protein as active ingredient developed with the aim of being comparable to an existing biological pharmaceutical product (the “reference pharmaceutical product”). There are no significant differences in quality, safety and effectiveness between biosimilars and reference pharmaceutical products.

Thornton & Ross to acquire established GSK Consumer Health brands

Huddersfield, June 07, 2019 – Thornton & Ross has expanded its Consumer Health business with a contract to acquire four UK skin care brands, as well as a paediatric cough remedy, from GlaxoSmithKline. Completion of the deal is expected to occur by August 2019.

The brands being acquired from GSK, all of which have the opportunity for revitalisation and accelerated growth, are: Oilatum, an emollient brand currently focused in the paediatric market; heritage antiseptic brand Savlon, which has been a medicine cabinet essential for generations; Eurax, a topical itch relief cream; Polytar, a coal-tar based dandruff shampoo that is a medical treatment for scalp conditions including psoriasis; and Tixylix, a range of paediatric cough liquids.

Head and Executive Vice President of Thornton & Ross, Roger Scarlett-Smith says: “These acquisitions demonstrate our ambition to be the leading company in Consumer Health. Our existing expertise in skincare and cough remedies puts us in a strong position to support and grow these acquisitions. We look forward to giving these brands a new home and a bright future.”

Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO

Bad Vilbel, September 3, 2018 – Peter Goldschmidt (53) succeeded Claudio Albrecht as the Chief Executive Officer of STADA Arzneimittel AG (‘STADA’ or ‘the Group’) with effect from September 1, 2018. Goldschmidt is an experienced generics manager and OTC expert who was most recently President of SANDOZ US, the global generics division of Novartis, and Head of North America. Goldschmidt will be focused on continuing STADA’s growth strategy that Albrecht successfully reinvigorated and advanced in 2017.

“Peter Goldschmidt is the right man that STADA needs in the driving seat going forward,” said Chairman of the Supervisory Board Günter von Au. “With his three decades of experience, I am confident he will ensure that STADA successfully retains its strong competitive position,” added von Au. He describes Goldschmidt as a “strong team player who has a long-term focus on building the portfolio and an excellent network in the pharmaceutical world”.

Originally from Höxter in East Westphalia, Goldschmidt came to STADA from the Novartis Group, where he held various senior management positions in Europe, Asia, and the US over the past 28 years. In his past position as the President of Sandoz USA and the Head of North America, he rapidly expanded the company’s generics and biosimilar business over the past five years to generate revenue in excess of USD 3 billion.

Previously, Peter Goldschmidt was also the Global Executive Member for Central and Eastern Europe for Sandoz, where he led Sandoz to a market leading position in generics and strongly grew its OTC business. He also held various senior leadership positions at Novartis Pharma in Asia and Europe during his career. “Naturally I have known STADA as a key player in the industry for many years, and I see enormous potential for the Group. Together with all employees we will strive to fully capitalise on the opportunities for growth,” announced the new CEO.

Goldschmidt intends to use the next 100 days to intensively get to know the Group, its partners, and its customers, and will then discuss his strategic priorities with his team. “I look forward to working with the highly experienced team at STADA to continue the Group’s long-term growth,” said the new CEO. Goldschmidt also described the excitement of the work ahead as another reason for joining STADA. “I am in complete alignment with our majority owners, Cinven and Bain Capital, on their strategy for building a company with long-term growth potential. Using the financial resources at their disposal, our focus remains on continuing to market a competitive portfolio and working closely with our global network of strategic development and production partners.”

Goldschmidt thanked Claudio Albrecht for the professional and amicable handover. Under the German government’s “cooling-off” regulation of 2009, Albrecht will not be taking a seat on the STADA Group’s Supervisory Board. “I am proud that, together with the high quality team at STADA and the Supervisory Board, we have successfully managed to turn STADA around, both in terms of business development and corporate governance and we will continue to focus on maintaining exemplary corporate governance standards and conduct. Naturally, I will continue to support the STADA Group and I wish Peter Goldschmidt and his team all the best,” said the outgoing CEO.

“Claudio Albrecht and his team played a fundamental role in setting out the Group’s strategy and initiating key process changes. We now have a great foundation that we can build on,” concluded Goldschmidt.

Günter von Au added: “On behalf of the Board of Stada and our major shareholders, I would like to thank Claudio for his exceptional contribution to STADA. He has worked tirelessly to redefine STADA’s growth strategy and to steer the Group towards its new path for success. We are very grateful for his dedication.”

Peter Goldshmidt and Claudio Albrecht
STADA's new CEO Peter Goldschmidt (left) thanked his predecessor Claudio Albrecht for the professional and friendly handover and got an initial overview of some of the company's best-selling products.

Derma Boy
Derma new business shows steady growth

November 2012
Steady growth from a new range of products in a new business area means development plans are succeeding for T&R Derma.

Our Derma range of emollient products to treat and manage eczema was launched in July 2010 at Britain’s leading dermatology congress, run by the British Association of Dermatology (BAD).

A new sales structure has been established to spearhead growth nationwide, and Dermatology Marketing Manager Janet Maclean has masterminded the launch campaign.

“It’s been slow but steady growth since we launched – which is exactly what we’re hoping for,” explained Janet. “It’s a completely new business area for us – so we haven’t just been launching a new range of products, we’ve been launching Thornton & Ross into a different market - the NHS. It’s part of the long-term strategy for business growth. Britain has a £140 million emollient market – growing by 10% every year due to lifestyle impacts, the rise in population, and the rise in the percentage of elderly. It’s an all-year-round business, not seasonal, and once someone is on an emollient they may use it for their life time. So it has huge potential for us, and we’re laying down the foundations for future growth.”

We have two product ranges within the T&R Derma portfolio. – the cost-effective Zeroderma range of four creams, 2 bath oil products and 1 ointment for hospitals and Primary Care Trusts, which is complemented by a unique, clinically proven product called Aquamol. Aquamol has a unique moisture-enhancing formula combining penetration enhancers and occlusive properties. Few comparable products are clinically proven and Aquamol has been shown to significantly improve eczema and the overall skin condition; significantly reduce skin itch; significantly reduce sleep disturbance and, crucially, reduce the need for topical corticosteroids.

News

Leading pharmaceutical company invests in seven-figure state-of-the-art facility

Huddersfield pharmaceutical company Thornton & Ross is expanding, with a new seven-figure state-of-the-art facility due to open at the beginning of January.

Click for more info

Thornton & Ross triumphant in industry awards

Huddersfield-based pharmaceutical company Thornton & Ross has received national recognition for six of its products at the national 2019 ‘Most Valuable Product’ (MVP) Awards in pharmacy.

Click for more info

Thornton & Ross launches alternative, cost-effective treatment for osteoporosis in UK

West Yorkshire-based pharmaceutical company Thornton & Ross (T&R) is launching an alternative, cost-effective treatment for osteoporosis.

Click for more info

Thornton & Ross to acquire established GSK Consumer Health brands

Thornton & Ross has expanded its Consumer Health business with a contract to acquire four UK skin care brands, as well as a paediatric cough remedy, from GlaxoSmithKline. Completion of the deal is expected to occur by August 2019.

Click for more info

Peter Goldschmidt to succeed Claudio Albrecht as STADA’s CEO

STADA Arzneimittel AG Appoints Peter Goldschmidt as CEO to suceed Claudio Albrecht.

Click for more info

STADA acquires EMEA rights to global anti-dandruff brand Nizoral from Janssen Pharmaceutica

STADA Arzneimittel AG is further strengthening its position in branded over-the-counter healthcare products.

Click for more info

Ladival wins 'Best Beach Sun Protection 2017'

Thornton & Ross is pleased to announce that Ladival Sun Protection Lotion SPF30 has won the 'Best Beach Sun Protection' in this year's Best Beauty by Stylist Awards 2017.

Click for more info

Thornton & Ross Ltd signs licensing agreement with Futura Medical

Thornton & Ross is pleased to announce it has entered in to a long-term licensing agreement with Futura Medical.

Click for more info

Thornton & Ross Ltd acquires Natures Aid Ltd

Thornton & Ross Ltd is pleased to announce that it has acquired the Natures Aid business, a leading UK manufacturer and distributor of premium quality branded vitamins, minerals, food supplements and herbal products.

Click for more info

>> News Archive